A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

Phase 2 Completed 30 enrolled Shanghai Zhongshan Hospital

NaSingle-groupOpen-labelTreatment

Summary

This study is expected to recruit 30 patients with unresectable HCC who will be treated with Donafenib combined with PD-1 + TACE. During the study period, the tumor efficacy and resectability will be evaluated by imaging examination every 6 weeks. Patients with successful transformation can choose hepatectomy or observation. During the study, safety evaluation and effectiveness evaluation will be carried out.

Timeline

Start: 2021-12-01
Primary completion: 2024-04-30
Completion: 2024-05-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Donafenib	Small molecule	0.1 mg	Oral

Indications

No indication recorded.